AstraZeneca Says Enhertu Received Positive Recommendations From CHMP For Gastric Cancer

AstraZeneca PLC (AZN.L) and Daiichi Sankyo's Enhertu received positive recommendation from European Union's Committee for Medicinal Products for Human Use (CHMP) to treat adults patients with HER2-positive gastric cancer, AstraZeneca said in a statement.

The positive opinion from the CHMP was based on results from the DESTINY-Gastric02 and the DESTINY-Gastric01 Phase II trials.

In DESTINY-Gastric02 study, Enhertu showed clinically meaningful efficacy, and improved overall survival compared to chemotherapy, was observed in DESTINY-Gastric01 study.

"If approved, Enhertu would be the first HER2-directed medicine for patients with advanced gastric cancer in the European Union in more than a decade,"said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca.

Enhertu is already approved in many countries including the US for locally advanced or metastatic HER2-positive gastric cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT